Article

Belkin Laser changes corporate name to Belkin Vision

The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.

BELKIN Laser announced Thursday it has changed its corporate name to BELKIN Vision.

BELKIN Laser announced Thursday it has changed its corporate name to BELKIN Vision.


BELKIN Vision, an Israeli-based medical device company, announced Thursday that the company will begin operating under the new name BELKIN Vision.

This corporate name change was determined as part of a strategic decision to better reflect the company's future plans, according to CEO/co-founder Daria Lemann Blumenthal.

Established in 2013, BELKIN was launched from with the goal of providing accessible glaucoma laser treatment to patients with the same ease as prescribing eye drops.

The company is working to develop technology centered around a transscleral approach to provide an automated laser treatment completed in one second.

The simplicity of the idea would allow the laser treatment to be administered by all eye care providers making first-line glaucoma treatment available for every patient worldwide, according to the company's website.

"We always imagined (starting the company) would transport us to the stage we're at today. Now, on the cusp of commercialization, we anticipate a multitude of exciting future applications and wanted to ensure that our company name aligned with that vision," Lemann Blumentha said, in a statement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.